The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence

Gabrielle L. McLemore, Benjamin Kest, Charles E. Inturrisi

Research output: Contribution to journalArticle

Abstract

In rodents, noncompetitive and competitive NMDA receptor antagonists have been shown to attenuate and, in some cases, reverse tolerance to the analgesic effects of morphine. However, the ability of these same excitatory amino acid (EAA) receptor antagonists to modulate morphine dependence is controversial, and very little is known about the role of AMPA receptors in morphine dependence. LY293558, A novel, systemically active, competitive AMPA receptor antagonist and the NMDA receptor antagonists, MK-801 and/or LY235959, were evaluated in tolerant or dependent CD-1 mice. In mice rendered tolerant by morphine injection or pellet implantation, continuous s.c. infusion of LY293558 (60 mg/kg per 24 h) or MK-801 (1 mg/kg per 24 h) attenuated the development of tolerance. Neither LY293558 nor MK-801 produced analgesia or altered the ED50 value of morphine. Continuous s.c. infusion of LY293558 (60 mg/kg per 24 h), MK-801 (1 mg/kg per 24 h) or LY235959 (12 mg/kg per 24 h) attenuated the development of acute (3 h) morphine dependence (i.e., decreased naloxone-precipitated withdrawal jumping). In contrast, continuous s.c. infusion of LY293558 (60 mg/kg per 24 h) or LY235959 (12 mg/kg per 24 h) did not significantly attenuate the development of chronic dependence produced by morphine pellet implantation. These data indicate that the development of morphine tolerance is more sensitive to modulating by EAA receptor antagonists than is the development of morphine dependence as assessed by naloxone-precipitated withdrawal jumping.

Original languageEnglish (US)
Pages (from-to)120-126
Number of pages7
JournalBrain Research
Volume778
Issue number1
DOIs
StatePublished - Dec 5 1997
Externally publishedYes

Fingerprint

tezampanel
Morphine Dependence
AMPA Receptors
LY 235959
Dizocilpine Maleate
Morphine
Excitatory Amino Acid Antagonists
Glutamate Receptors
Naloxone
N-Methyl-D-Aspartate Receptors
Aptitude
Analgesia
Analgesics
Rodentia
Injections

Keywords

  • AMPA receptor
  • Excitatory amino acidΛY293558
  • Morphine dependence
  • Morphine tolerance
  • Withdrawal jumping

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. / McLemore, Gabrielle L.; Kest, Benjamin; Inturrisi, Charles E.

In: Brain Research, Vol. 778, No. 1, 05.12.1997, p. 120-126.

Research output: Contribution to journalArticle

McLemore, Gabrielle L. ; Kest, Benjamin ; Inturrisi, Charles E. / The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. In: Brain Research. 1997 ; Vol. 778, No. 1. pp. 120-126.
@article{0a7e8791abcc42fd85987d8e191c69f2,
title = "The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence",
abstract = "In rodents, noncompetitive and competitive NMDA receptor antagonists have been shown to attenuate and, in some cases, reverse tolerance to the analgesic effects of morphine. However, the ability of these same excitatory amino acid (EAA) receptor antagonists to modulate morphine dependence is controversial, and very little is known about the role of AMPA receptors in morphine dependence. LY293558, A novel, systemically active, competitive AMPA receptor antagonist and the NMDA receptor antagonists, MK-801 and/or LY235959, were evaluated in tolerant or dependent CD-1 mice. In mice rendered tolerant by morphine injection or pellet implantation, continuous s.c. infusion of LY293558 (60 mg/kg per 24 h) or MK-801 (1 mg/kg per 24 h) attenuated the development of tolerance. Neither LY293558 nor MK-801 produced analgesia or altered the ED50 value of morphine. Continuous s.c. infusion of LY293558 (60 mg/kg per 24 h), MK-801 (1 mg/kg per 24 h) or LY235959 (12 mg/kg per 24 h) attenuated the development of acute (3 h) morphine dependence (i.e., decreased naloxone-precipitated withdrawal jumping). In contrast, continuous s.c. infusion of LY293558 (60 mg/kg per 24 h) or LY235959 (12 mg/kg per 24 h) did not significantly attenuate the development of chronic dependence produced by morphine pellet implantation. These data indicate that the development of morphine tolerance is more sensitive to modulating by EAA receptor antagonists than is the development of morphine dependence as assessed by naloxone-precipitated withdrawal jumping.",
keywords = "AMPA receptor, Excitatory amino acidΛY293558, Morphine dependence, Morphine tolerance, Withdrawal jumping",
author = "McLemore, {Gabrielle L.} and Benjamin Kest and Inturrisi, {Charles E.}",
year = "1997",
month = "12",
day = "5",
doi = "10.1016/S0006-8993(97)00985-2",
language = "English (US)",
volume = "778",
pages = "120--126",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence

AU - McLemore, Gabrielle L.

AU - Kest, Benjamin

AU - Inturrisi, Charles E.

PY - 1997/12/5

Y1 - 1997/12/5

N2 - In rodents, noncompetitive and competitive NMDA receptor antagonists have been shown to attenuate and, in some cases, reverse tolerance to the analgesic effects of morphine. However, the ability of these same excitatory amino acid (EAA) receptor antagonists to modulate morphine dependence is controversial, and very little is known about the role of AMPA receptors in morphine dependence. LY293558, A novel, systemically active, competitive AMPA receptor antagonist and the NMDA receptor antagonists, MK-801 and/or LY235959, were evaluated in tolerant or dependent CD-1 mice. In mice rendered tolerant by morphine injection or pellet implantation, continuous s.c. infusion of LY293558 (60 mg/kg per 24 h) or MK-801 (1 mg/kg per 24 h) attenuated the development of tolerance. Neither LY293558 nor MK-801 produced analgesia or altered the ED50 value of morphine. Continuous s.c. infusion of LY293558 (60 mg/kg per 24 h), MK-801 (1 mg/kg per 24 h) or LY235959 (12 mg/kg per 24 h) attenuated the development of acute (3 h) morphine dependence (i.e., decreased naloxone-precipitated withdrawal jumping). In contrast, continuous s.c. infusion of LY293558 (60 mg/kg per 24 h) or LY235959 (12 mg/kg per 24 h) did not significantly attenuate the development of chronic dependence produced by morphine pellet implantation. These data indicate that the development of morphine tolerance is more sensitive to modulating by EAA receptor antagonists than is the development of morphine dependence as assessed by naloxone-precipitated withdrawal jumping.

AB - In rodents, noncompetitive and competitive NMDA receptor antagonists have been shown to attenuate and, in some cases, reverse tolerance to the analgesic effects of morphine. However, the ability of these same excitatory amino acid (EAA) receptor antagonists to modulate morphine dependence is controversial, and very little is known about the role of AMPA receptors in morphine dependence. LY293558, A novel, systemically active, competitive AMPA receptor antagonist and the NMDA receptor antagonists, MK-801 and/or LY235959, were evaluated in tolerant or dependent CD-1 mice. In mice rendered tolerant by morphine injection or pellet implantation, continuous s.c. infusion of LY293558 (60 mg/kg per 24 h) or MK-801 (1 mg/kg per 24 h) attenuated the development of tolerance. Neither LY293558 nor MK-801 produced analgesia or altered the ED50 value of morphine. Continuous s.c. infusion of LY293558 (60 mg/kg per 24 h), MK-801 (1 mg/kg per 24 h) or LY235959 (12 mg/kg per 24 h) attenuated the development of acute (3 h) morphine dependence (i.e., decreased naloxone-precipitated withdrawal jumping). In contrast, continuous s.c. infusion of LY293558 (60 mg/kg per 24 h) or LY235959 (12 mg/kg per 24 h) did not significantly attenuate the development of chronic dependence produced by morphine pellet implantation. These data indicate that the development of morphine tolerance is more sensitive to modulating by EAA receptor antagonists than is the development of morphine dependence as assessed by naloxone-precipitated withdrawal jumping.

KW - AMPA receptor

KW - Excitatory amino acidΛY293558

KW - Morphine dependence

KW - Morphine tolerance

KW - Withdrawal jumping

UR - http://www.scopus.com/inward/record.url?scp=0031555395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031555395&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(97)00985-2

DO - 10.1016/S0006-8993(97)00985-2

M3 - Article

C2 - 9462883

AN - SCOPUS:0031555395

VL - 778

SP - 120

EP - 126

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -